U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07173179) titled 'Papillary Epinephrine Injection Combined With Rectal Indomethacin' on Sept. 08.
Brief Summary: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common and one of the most undesirable major adverse events after endoscopic retrograde cholangiopancreatography (ERCP), causing significant morbidity and even mortality. The incidence rate is almost 15% in high-risk patients and no less than 3% in average-risk patients.
Many factors contribute to PEP, such as patient-related and endoscopist-related factors, but mainly two mechanisms are considered in terms of physiopathology: papillary edema caused by mec...